Year: 2022

PLEASANTON, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Healthcare Triangle, Inc (HCTI), a leading provider of cloud and digital transformation, managed services and data analytics platform for healthcare and life sciences industry reported results for the quarter ended September 30, 2022. All comparisons are to the same year ago period unless otherwise noted. Q3 2022 Financial HighlightsRevenue increased 48% to $11.9 million YoY Gross margin at 29% R&D costs at $1.5 million Cash $4.1 millionQ3 2022 Operational HighlightsHealthcare Triangle Inc, raised USD 6.5M through private placement  Launched our services in Singapore to grow digital healthcare in the Asia Pacific region Implemented MEDITECH Expanse for Chronic Care Management for a Primary Healthcare Centre Standardized cloud platform using IaC (Infrastructure as Code)...

– Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 – – Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6 Deficiency on track for the first quarter of 2023 – – Liquidity and capital resources as of quarter end funds cash flow requirements into the second quarter of 2024 – BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2022 and provided recent business highlights. “Progress continues with our ongoing Phase 1/2 clinical trials of INZ-701 in patients with ENPP1 Deficiency and...

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and nine months ended September 30, 2022 and provided a business update. Highlights of the third quarter of 2022 and recent weeks include: Financial HighlightsCash and cash equivalents were $16.8 million as of September 30, 2022, compared with $29.2 million as of December 31, 2021 Net loss for the third quarter of 2022 was $14.4 million, or $6.41 per share, which included a loss on goodwill impairment of $8.9 million, or an impairment of $3.94 per share, compared with net loss for the third quarter of 2021 of $3.7 million, or $2.09...

OLD GREENWICH, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) — Hudson Global, Inc. (Nasdaq: HSON) (“Hudson Global” or “the Company”), a leading global total talent solutions company, announced today financial results for the third quarter ended September 30, 2022. 2022 Third Quarter SummaryRevenue of $48.7 million increased 8.2% from the third quarter of 2021 and 15.9% in constant currency. Adjusted net revenue of $24.2 million increased 34.2% from the third quarter of 2021 and 41.8% in constant currency. Net income was $1.0 million, or $0.30 per diluted share, compared to net income of $1.5 million, or $0.49 per diluted share, for the third quarter of 2021. Adjusted net income per diluted share (non-GAAP measure)* was $0.58 compared to adjusted net income per diluted share of $0.78 in the third quarter of 2021. Adjusted...

Third-quarter Total Revenue of $7.6 Million up 31% Year over Year Reports Positive EBITDA of $0.7 Million Total Backlog of Open Orders of $16.6 Million on Strong Bookings HOPEWELL JUNCTION, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) — eMagin Corporation, or the “Company,” (NYSE American: EMAN), a leader in the development, design, and manufacture of Active-Matrix OLED microdisplays for high-resolution, AR/VR and other near-eye imaging products, today announced results for its third quarter ended September 30, 2022. “eMagin’s third quarter was highlighted by a 31% year-over-year revenue increase leading to improved gross margins and positive EBITDA, along with new business wins and continued growth in our backlog of open orders,” said eMagin CEO Andrew G. Sculley. “Our total revenues rose to $7.6 million, compared to $5.8 million a year...

Net Revenue for the Quarter Was $12.7 Million; On a Constant Currency Basis Net Revenue Increased 15.6% to $15.5 MillionRecurring Revenue (SaaS and Support) Was $6 Million; On a Constant Currency Basis Recurring Revenue increased 16.6% to $7.3 MillionRobust Sales Pipeline exceeding $200 millionNew Partnership with Amazon Web ServicesNew Otoz Agreement with a Tier 1 Automotive Company in the U.S to Manage the Back- Office Operations for Vehicle SubscriptionsCompany Launch of Flex Product Offering Reflects Ongoing Focus on Product InnovationCALABASAS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, reported results for the fiscal first quarter ended September 30, 2022. Fiscal First Quarter 2023 and Recent Operational...

Company completed a public offering for aggregate gross proceeds of $16.8 million Majority of clinical sites now open in clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced plans to initiate second clinical trial to evaluate QRX003 in Netherton Syndrome patients currently receiving off-label systemic therapy Signed an international partnership agreement for QRX003 during the third quarter 2022 Research programs with QUT continue to progress towards initiation of clinical testing in 2023 Company continues to work with its distribution partnership network to explore opportunities to participate in Early Access Programs for QRX003ASHBURN, Va., Nov. 10, 2022 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on...

VANCOUVER, British Columbia and BONHAM, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) — Kelso Technologies Inc. (“Kelso” or the “Company”), (TSX: KLS), (NYSE American: KIQ) reports that the Company has released the unaudited consolidated interim financial statements and Management Discussion and Analysis (the “MD&A”) for the nine months ended September 30, 2022. The unaudited consolidated interim financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). All amounts herein are expressed in United States dollars (the Company’s functional currency) unless otherwise indicated. The Company’s unaudited interim consolidated financial statements and MD&A for the nine months ending September 30, 2022 were approved by the...

ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. “Stereotaxis continues to demonstrate robust commercial and technological progress,” said David Fischel, Chairman and CEO. “We received two system orders in the third quarter, and have already received two additional signed purchase contracts as we start the fourth quarter, reflecting continued global demand for our robotic technology. Our growing system backlog of over $13 million, along with a healthy capital pipeline, sets us up well for the coming year.” “Alongside this commercial execution, we are making significant progress on a robust innovation strategy. The CE Mark submission...

Company announcement No. 51 / 2022 Zealand Pharma Announces Financial Results for the First Nine Months of 2022 Copenhagen, Denmark November 10, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the interim report for the three and nine months ended September 30, 2022 and provided a corporate update. Key strategic objectives achieved Adam Steensberg, President and Chief Executive at Zealand Pharma said: “Zealand has continued to execute and deliver on key objectives in the third quarter. In September, we completed our stated objective of securing partnerships for our marketed products through a license and development agreement with Novo Nordisk, a global leader in diabetes, to commercialize Zegalogue®. “Within...